163 related articles for article (PubMed ID: 27986127)
1. Irisin and Myostatin Levels in Patients with Graves' Disease.
Yalcin MM; Akturk M; Tohma Y; Cerit ET; Altinova AE; Arslan E; Yetkin I; Toruner FB
Arch Med Res; 2016 Aug; 47(6):471-475. PubMed ID: 27986127
[TBL] [Abstract][Full Text] [Related]
2. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
3. Association between circulating irisin levels and epicardial fat in patients with treatment-naïve overt hyperthyroidism.
Şahin M; Canpolat AG; Çorapçioğlu D; Canpolat U; Emral R; Uysal AR
Biomarkers; 2018 Dec; 23(8):742-747. PubMed ID: 29862847
[TBL] [Abstract][Full Text] [Related]
4. Decreased serum level of IL-7 in patients with active Graves' disease.
Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
[TBL] [Abstract][Full Text] [Related]
5. Serum irisin levels and thyroid function--newly discovered association.
Ruchala M; Zybek A; Szczepanek-Parulska E
Peptides; 2014 Oct; 60():51-5. PubMed ID: 25102448
[TBL] [Abstract][Full Text] [Related]
6. Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?
García-Fontana B; Reyes-García R; Morales-Santana S; Ávila-Rubio V; Muñoz-Garach A; Rozas-Moreno P; Muñoz-Torres M
Endocrine; 2016 Apr; 52(1):54-62. PubMed ID: 26438394
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-21 is associated with disease activity in patients with Graves' disease.
Zhang J; Zeng H; Ren M; Yan H; Xu M; Feng Z; Liang W; Yang C; Cheng H; Ding H; Yan L
Endocrine; 2014 Aug; 46(3):539-48. PubMed ID: 24287789
[TBL] [Abstract][Full Text] [Related]
8. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
9. Characterization and clinical relevance of circulating CD4+CD28- T cells in Graves' disease.
Wang F; Chen L; Shen Q; Liu T; Jiang L; Gu X; Chen L; Sun J; Liu C
Immunol Lett; 2015 May; 165(1):47-51. PubMed ID: 25839128
[TBL] [Abstract][Full Text] [Related]
10. Circulating Levels of Orexin-A, Nesfatin-1, Agouti-Related Peptide, and Neuropeptide Y in Patients with Hyperthyroidism.
Tohma Y; Akturk M; Altinova A; Yassibas E; Cerit ET; Gulbahar O; Arslan M; Sanlier N; Toruner F
Thyroid; 2015 Jul; 25(7):776-83. PubMed ID: 25915725
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of irisin is elevated in hypothyroidism, a case-control study.
Ateş İ; Altay M; Topçuoğlu C; Yılmaz FM
Arch Endocrinol Metab; 2016 Apr; 60(2):95-100. PubMed ID: 26201007
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.
Sieminska L; Niedziolka D; Pillich A; Kos-Kudla B; Marek B; Nowak M; Borgiel-Marek H
J Endocrinol Invest; 2008 Sep; 31(9):745-9. PubMed ID: 18997483
[TBL] [Abstract][Full Text] [Related]
13. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
[TBL] [Abstract][Full Text] [Related]
14. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
15. Myokines in Acromegaly: An Altered Irisin Profile.
Mizera Ł; Halupczok-Żyła J; Kolačkov K; Zembska A; Grzegrzółka J; Jędrzejuk D; Bolanowski M; Daroszewski J
Front Endocrinol (Lausanne); 2021; 12():728734. PubMed ID: 34795636
[TBL] [Abstract][Full Text] [Related]
16. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
Harvengt J; Boizeau P; Chevenne D; Zenaty D; Paulsen A; Simon D; Guilmin Crepon S; Alberti C; Carel JC; Léger J
Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNA-1a is a biomarker of Graves' disease patients with atrial fibrillation.
Wang F; Zhang SJ; Yao X; Tian DM; Zhang KQ; She DM; Guo FF; Zhai QW; Ying H; Xue Y
Endocrine; 2017 Jul; 57(1):125-137. PubMed ID: 28547036
[TBL] [Abstract][Full Text] [Related]
18. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
[TBL] [Abstract][Full Text] [Related]
19. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
[TBL] [Abstract][Full Text] [Related]
20. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
